Author

Qian Liang

Army Medical UniversityPrimary ORCID profile (0009-0001-9657-0280 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Qian LiangiD1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Anneliese O. SpeakiD· 1 shared Brian M. OrtmanniD· 1 shared Dan Cai· 1 shared E GuojiiD· 1 shared Erlong ZhangiD· 1 shared Gang XuiD· 1 shared Guibo LiiD· 1 shared Hongyu Xue· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anneliese O. SpeakORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

VHL synthetic lethality screens uncover CBF-beta as a negative regulator of STING

James A.C. Bertlin, Tekle Pauzaite, Qian Liang, Niek Wit, James C. Williamson, Jia Jhing Sia, Nicholas J. Matheson, Brian M. Ortmann, Thomas J. Mitchell, Anneliese O. Speak, Qing Zhang, James A. Nathan

The paper identifies CBF-beta as a negative regulator of STING through synthetic lethality screens in VHL-null ccRCC cells, showing its role in type I interferon signaling and tumor growth.

Nature Communications · Mar 12, 2026Peer-reviewedCancer Biology

Hypobaric hypoxia drives citrate cycle reprogramming to suppress tumor progression

Yixing Gao, Xiuju He, E Guoji, Yan Wang, Shirui Huang, Dan Cai, Yumei Deng, Ping Gan, Rui Feng, Qian Liang, Ziyi Tang, Gang Xu, Jian Chen, Hongyu Xue, Qiutong Wang, , Erlong Zhang

This study shows hypobaric hypoxia suppresses tumor progression by reprogramming the citrate cycle and inhibiting the HIF-1 pathway, enhancing antitumor immune response and improving therapy outcomes.

bioRxiv · Aug 15, 2025 · PreprintCancer Biology